Business Description
InspireMD Inc
NAICS : 339112
SIC : 3841
ISIN : US45779A8615
Description
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 24.47 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -3.15 | |||||
| Beneish M-Score | -2.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -46.2 | |||||
| 3-Year EBITDA Growth Rate | 49.7 | |||||
| 3-Year EPS without NRI Growth Rate | 51 | |||||
| 3-Year FCF Growth Rate | 51.5 | |||||
| 3-Year Book Growth Rate | -21.2 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.4 | |||||
| 9-Day RSI | 54.99 | |||||
| 14-Day RSI | 49.1 | |||||
| 6-1 Month Momentum % | -27.69 | |||||
| 12-1 Month Momentum % | 58.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.34 | |||||
| Quick Ratio | 6.99 | |||||
| Cash Ratio | 6.48 | |||||
| Days Inventory | 148.71 | |||||
| Days Sales Outstanding | 79.65 | |||||
| Days Payable | 59.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -88.1 | |||||
| Shareholder Yield % | 0.06 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 29.12 | |||||
| Operating Margin % | -340.74 | |||||
| Net Margin % | -320.97 | |||||
| FCF Margin % | -270.06 | |||||
| ROE % | -62.09 | |||||
| ROA % | -50.84 | |||||
| ROIC % | -397.54 | |||||
| ROC (Joel Greenblatt) % | -875.92 | |||||
| ROCE % | -61.86 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.65 | |||||
| PB Ratio | 1.22 | |||||
| Price-to-Tangible-Book | 1.22 | |||||
| EV-to-EBIT | -0.57 | |||||
| EV-to-EBITDA | -0.57 | |||||
| EV-to-Revenue | 1.93 | |||||
| EV-to-Forward-Revenue | 2.19 | |||||
| EV-to-FCF | -0.72 | |||||
| Price-to-Net-Current-Asset-Value | 1.34 | |||||
| Price-to-Net-Cash | 1.57 | |||||
| Earnings Yield (Greenblatt) % | -175.44 | |||||
| FCF Yield % | -32.37 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers